Opus Genetics is trading at $4.28, up 5.68%, in pre-market after reporting positive findings from its OPGx-BEST1 and OPGx-LCA5 programs. - Retinal sensitivity improved in three of four evaluable low-dose participants; treated participants also had sustained visual-function gains. - The company said its LCA5 program is moving toward Phase 3 dosing in Q4 2026. - No separate October 16 announcement surfaced in the company releases reviewed.